Video Experimental Relacionado
Updated: Jul 4, 2026
10:21
Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
Published on: September 20, 2024
Puntuaciones poligénicas multirasgo para la EPOC y exacerbaciones de la EPOC implican proteínas tratables
Chengyue Zhang1, Iain R Konigsberg2, Yixuan He3
1Channing Division of Network Medicine, Mass General Brigham, Boston, United States of America.
JCI insight
|February 19, 2026
Resumen
Una nueva puntuación poligénica multirasgo (PRS) mejora la predicción de la enfermedad pulmonar obstructiva crónica (EPOC) y las exacerbaciones. Este enfoque también identifica posibles dianas farmacológicas para la medicina de precisión en el manejo de la EPOC.
Área de la Ciencia:
- Genética y Bioinformática; Neumología; Farmacogenómica
Sus antecedentes:
- La enfermedad pulmonar obstructiva crónica (EPOC) representa una carga sanitaria significativa, lo que requiere mejores estrategias de predicción y manejo.; Los modelos predictivos actuales para la EPOC y sus exacerbaciones tienen limitaciones en precisión y alcance.; La identificación de nuevas dianas terapéuticas es crucial para avanzar en la medicina de precisión en la EPOC.
Objetivo del estudio:
- Desarrollar y validar una puntuación poligénica multirasgo (PRSmulti) para predecir el riesgo de EPOC y exacerbaciones.; Evaluar el rendimiento de PRSmulti en diversas poblaciones.; Identificar proteínas asociadas con PRS para la posible diana terapéutica en la EPOC.
Principales métodos:
- Se utilizó el marco PRSmix+ para construir un PRS compuesto (PRSmulti) a partir de 7 rasgos seleccionados en la cohorte COPDGene.; Se validaron las asociaciones de PRSmulti con el estado de EPOC y la frecuencia de exacerbaciones en múltiples cohortes grandes y diversas (COPDGene, ECLIPSE, MassGeneral Brigham Biobank, All of Us).; Se emplearon modelos de predicción de proteínas con datos de GWAS y se validaron los hallazgos con datos proteómicos de COPDGene y UK Biobank para identificar proteínas relacionadas con PRS.
Principales resultados:
- El PRSmulti demostró asociaciones significativas con el estado de EPOC (OR 1.58) y la frecuencia de exacerbaciones (beta 0.21) en el metaanálisis.; El PRSmulti mostró un rendimiento predictivo superior en comparación con el PRS monotipo tradicional en todas las cohortes probadas.; Se identificaron 73 proteínas asociadas con PRS, con 25 vinculadas a fármacos existentes o en investigación, incluyendo dianas notables como RAGE/sRAGE, IL1RL1 y SCARF2.
Conclusiones:
- El PRS multirasgo ofrece un método robusto para mejorar la predicción del riesgo de EPOC y exacerbaciones.; La integración de PRS con datos proteómicos identificó con éxito dianas de proteínas tratables.; Este enfoque representa una estrategia prometedora para el desarrollo de intervenciones de medicina personalizada para la EPOC.
Videos de Conceptos Relacionados
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...